Viz.ai Receives FDA Clearance for Automated Computed Tomography Perfusion (CTP) Software

Monday, April 23, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

Automated CTP functionality added to comprehensive product suite

SAN FRANCISCO, April 23, 2018 /PRNewswire/ -- Viz.ai, Inc., an applied artificial intelligence healthcare company, today

announced that the U.S. Food and Drug Administration (FDA) has cleared Viz CTP through the 510(k) pathway. Viz CTP offers image processing software to view and analyze functional and dynamic CT perfusion images. This clearance offers healthcare providers another important tool for automated cerebral-image analysis.

With the addition of Viz CTP, Viz.ai now offers perfusion analysis to complement a comprehensive suite of technology, which provides automated large vessel occlusion (LVO) stroke identification, stroke triage and LVO notification, patient selection, HIPAA compliant communication, mobile medical image viewing and transport coordination.

"In stroke, good patient outcomes can come down to a matter of minutes," said Dr. Chris Mansi, neurosurgeon, Chief Executive Officer and Co-Founder of Viz.ai, Inc. "We are proud to offer hospital systems a comprehensive solution that can facilitate end-to-end care coordination and create efficiencies in acute stroke pathways to help get  the right patient to the right doctor at the right time."

About StrokeStroke is a leading cause of permanent disability, death and healthcare costs globally. According to the American Heart Association/American Stroke Association (AHA/ASA), stroke is the fifth leading cause of death in the U.S. and a leading cause of disability. When a stroke occurs, and the flow of oxygen-rich blood to a portion of the brain is blocked, 2 million brain cells die every minute meaning "time is brain".

About Viz.ai, Inc.Viz.ai, Inc. is an applied artificial intelligence healthcare company that works alongside physicians to improve acute medical care. The Viz LVO Stroke Platform leverages advanced deep learning to communicate time-sensitive information about patients straight to a specialist who can intervene and treat.

Viz.ai, Inc., based in San Francisco and Tel Aviv, is financially backed by former Google CEO Eric Schmidt's venture capital firm, Innovation Endeavors and by Danhua Capital (DHVC). Viz.ai is the first company to receive FDA clearance for an Artificial intelligence based Computer-Aided Triage and Notification System.

For more information, visit http://www.Viz.ai, follow us on Twitter  and find us on LinkedIn.

Media Contact  Christy Maginn  Christy.maginn@bm.com   (646) 280-5210

Cision View original content:http://www.prnewswire.com/news-releases/vizai-receives-fda-clearance-for-automated-computed-tomography-perfusion-ctp-software-300634361.html

SOURCE Viz.ai, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store